Literature DB >> 21446934

The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer.

Riccardo Schiavina1, Fabio Manferrari, Marco Garofalo, Alessandro Bertaccini, Valerio Vagnoni, Mascia Guidi, Marco Borghesi, Alessandro Baccos, Antonio Maria Morselli-Labate, Sergio Concetti, Giuseppe Martorana.   

Abstract

OBJECTIVE: • To assess the impact of pelvic lymph node dissection (PLND) and of the number of lymph nodes (LNs) retrieved during radical prostatectomy (RP) on biochemical relapse (BCR) in pNX/0/1 patients with prostate cancer according to the clinical risk of lymph node invasion (LNI). PATIENTS AND METHODS: • We evaluated 872 pT2-4 NX/0/1 consecutive patients submitted to RP between October 1995 and June 2009, with the following inclusion criteria: (i) a follow-up period ≥12 months; (ii) the avoidance of neoadjuvant hormonal therapy or adjuvant hormonal and/or adjuvant radiotherapy; (iii) the availability of complete follow-up data; (iv) no pathological T0 disease; (v) complete data regarding the clinical stage and Gleason score (Gs), the preoperative prostate-specific antigen (PSA) level and the pathological stage. • The patients were stratified as having low risk (cT1a-T2a and cGs ≤6 and PSA level < 10 ng/mL), intermediate risk (cT2b-T2c or cGs = 7 or PSA level = 10-19.9) or high risk of LNI (cT3 or cGs = 8-10 or PSA level ≥ 20). • The 872 patients were divided into two LN groups according to the number of LNs retrieved: group 1 had no LN or one to nine LNs removed; group 2 had 10 or more LNs. • The variables analysed were LN group, age, PSA level, clinical and pathological stage and Gs, surgical margin status, LN status and number of LN metastases; the primary endpoint was the BCR-free survival.
RESULTS: • The mean follow-up was 55.8 months. • Of all the patients, 305 (35%) were pNx and 567 (65.0%) were pN0/1. • Of the 567 patients submitted to PLND, the mean number of LNs obtained was 10.9, and 49 (8.6%) were pN1. • In the 402 patients at low risk of LNI, LN group was not a significant predictor of BCR at univariate analysis, while in the 470 patients at intermediate and high risk of LNI, patients with ≥ 10 LNs removed had a significantly lower BCR-free survival at univariate and multivariate analysis.
CONCLUSION: • In our study population, a more extensive PLND positively affects the BCR-free survival regardless of the nodal status in intermediate- and high-risk prostate cancer.
© 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21446934     DOI: 10.1111/j.1464-410X.2010.10016.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  14 in total

1.  Multicenter evaluation of guideline adherence for pelvic lymph node dissection in patients undergoing open retropubic vs. laparoscopic or robot assisted radical prostatectomy according to the recent German S3 guideline on prostate cancer.

Authors:  Angelika Borkowetz; Johannes Bruendl; Martin Drerup; Jonas Herrmann; Hendrik Isbarn; Burkhard Beyer
Journal:  World J Urol       Date:  2018-02-09       Impact factor: 4.226

2.  Effect of Gleason scores of lymph node metastases on prognosis of patients with prostate cancer.

Authors:  Kyungtae Ko; In Gab Jeong; Woo Suk Choi; Ju Hyun Lim; Ja Hee Suh; Ja Hyeon Ku; Yangsoon Park; Kyung Cheol Moon; Hyeon Hoe Kim; Choung-Soo Kim; Cheol Kwak
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 3.  Is extended pelvic lymph node dissection for prostate cancer the only recommended option? A systematic over-view of the literature.

Authors:  Thomas Rees; Nicholas Raison; Mohammed Iqbal Sheikh; Zahra Jaffry; Sanjeev Madaan; Ben Challacombe; Kamran Ahmed; Prokar Dasgupta
Journal:  Turk J Urol       Date:  2016-12

4.  Cost-effectiveness comparison between neoadjuvant chemohormonal therapy and extended pelvic lymph node dissection in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis.

Authors:  Teppei Matsumoto; Shingo Hatakeyama; Teppei Ookubo; Koji Mitsuzuka; Shintaro Narita; Takamitsu Inoue; Shinichi Yamashita; Takuma Narita; Takuya Koie; Sadafumi Kawamura; Tatsuo Tochigi; Norihiko Tsuchiya; Tomonori Habuchi; Yoichi Arai; Chikara Ohyama
Journal:  Med Oncol       Date:  2017-10-31       Impact factor: 3.064

5.  Anatomic extent of pelvic lymph node dissection: impact on long-term cancer-specific outcomes in men with positive lymph nodes at time of radical prostatectomy.

Authors:  Trinity J Bivalacqua; Phillip M Pierorazio; Michael A Gorin; Mohamad E Allaf; H Ballentine Carter; Patrick C Walsh
Journal:  Urology       Date:  2013-09       Impact factor: 2.649

6.  Is More Always Better? An Assessment of the Impact of Lymph Node Yield on Outcome for Clinically Localized Prostate Cancer with Low/Intermediate Risk Pathology (pT2-3a/pN0) Managed with Prostatectomy Alone.

Authors:  Steven N Seyedin; Darrion L Mitchell; Sarah L Mott; J Kyle Russo; Chad R Tracy; Anthony N Snow; Jessica R Parkhurst; Mark C Smith; John M Buatti; John M Watkins
Journal:  Pathol Oncol Res       Date:  2017-10-27       Impact factor: 3.201

7.  Determinants of long-term survival of patients with locally advanced prostate cancer: the role of extensive pelvic lymph node dissection.

Authors:  M Moschini; N Fossati; F Abdollah; G Gandaglia; V Cucchiara; P Dell'Oglio; S Luzzago; S F Shariat; F Dehò; A Salonia; F Montorsi; A Briganti
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-11-10       Impact factor: 5.554

Review 8.  Robotic radical prostatectomy in high-risk prostate cancer: current perspectives.

Authors:  Abdullah Erdem Canda; Mevlana Derya Balbay
Journal:  Asian J Androl       Date:  2015 Nov-Dec       Impact factor: 3.285

Review 9.  Current technique and results for extended pelvic lymph node dissection during robot-assisted radical prostatectomy.

Authors:  Roger Li; Firas G Petros; Janet B Kukreja; Stephen B Williams; John W Davis
Journal:  Investig Clin Urol       Date:  2016-12-08

10.  Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.

Authors:  Ning Xu; Hui-Jun Chen; Shao-Hao Chen; Xue-Yi Xue; Hong Chen; Qing-Shui Zheng; Yong Wei; Xiao-Dong Li; Jin-Bei Huang; Hai Cai; Xiong-Lin Sun
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.